ACIP关于12-15岁青少年使用辉瑞-BioNTech COVID-19疫苗的临时建议
2021年5月10日FDA将辉瑞-BioNTech COVID-19疫苗紧急使用授权扩大至12-15岁青少年,5月12日ACIP基于EtR框架和GRADE方法发布该人群接种的临时建议。疫苗为2剂肌内注射(每剂30 μg,0.3 mL),间隔3周。
要点
- ACIP建议12-15岁青少年接种辉瑞-BioNTech COVID-19疫苗。
- 疫苗为2剂肌内注射,每剂30 μg(0.3 mL),间隔3周。
- 该建议为临时性,将随新信息更新。
核心结论
- ACIP发布临时建议,支持12-15岁青少年使用辉瑞-BioNTech COVID-19疫苗预防COVID-19。
研究设计与样本
- ACIP依据Evidence to Recommendation框架和GRADE方法形成临时建议,基于FDA扩大紧急使用授权。
主要发现
- 2021年5月10日FDA将辉瑞-BioNTech疫苗紧急使用授权扩大至12-15岁青少年。
关键数值与推荐
- 辉瑞-BioNTech COVID-19疫苗为2剂肌内注射,每剂30 μg(0.3 mL),间隔3周。
- 2020年12月11日FDA对≥16岁人群发布紧急使用授权,12月12日ACIP发布同年龄组临时建议。
- 2021年5月12日ACIP发布12-15岁青少年接种的临时建议。
临床怎么用
- 按2剂、间隔3周方案为12-15岁青少年接种辉瑞-BioNTech COVID-19疫苗。
- 该建议为临时性,需关注后续更新。
局限性
- 该建议为临时性,将随额外信息更新。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. Vaccination with the Pfizer-BioNTech COVID-19 vaccine consists of 2 intramuscular doses (30 μg, 0.3 mL each) administered 3 weeks apart. On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for use of the Pfizer-BioNTech COVID-19 vaccine (Pfizer, Inc; Philadelphia, Pennsylvania) in persons aged ≥16 years (1); on December 12, 2020, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation for use of the vaccine in the same age group (2). As of May 12, 2021, approximately 141.6 million doses of the Pfizer-BioNTech COVID-19 vaccine had been administered to persons aged ≥16 years.* On May 10, 2021, FDA expanded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include adolescents aged 12-15 years (1). On May 12, 2021, ACIP issued an interim recommendation† for use of the Pfizer-BioNTech COVID-19 vaccine in adolescents aged 12-15 years for the prevention of COVID-19. To guide its deliberations regarding the vaccine, ACIP used the Evidence to Recommendation (EtR) Framework,§ using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.¶ The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in persons aged ≥12 years under an EUA is interim and will be updated as additional information becomes available.
引用
- Wallace M, Woodworth KR, Gargano JW, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Adolescents Aged 12-15 Years - United States, May 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34014913. doi:10.15585/mmwr.mm7020e1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。